A Study in Patients With Metastatic Castration-Resistant Prostate Cancer

Summary

The goal of this clinical trial is to find out if FX-111 is safe enough to permit further studies in adult male participants with metastatic castration-resistant prostate cancer (mCRPC). It will also study the drug's pharmacokinetics (how the body breaks down FX-111) and how well FX-111 treats mCRPC. The main questions it aims to answer are: What are the side effects of FX-111? Does FX-111 work to reduce or prevent progression of mCRPC? The study doctor will oversee participants' treatment with FX-111 and ask about any side effects.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Metastatic Castration Resistant Prostate Cancer
• mCRPC
• mCRPC (Metastatic Castration-resistant Prostate Cancer)
• Prostatic Neoplasms
• Prostatic Neoplasms, Castration-Resistant
• mCRPC or Advanced/Metastatic Solid Tumors
• mCRPC, Metastatic Castration Resistant Prostate Cancer
• Neoplasms Prostate
• Neoplasms of Prostate

Eligibility basics and study details

Study type

Interventional

Phase

Phase 1

Ages

18 years and older

Sex

Male

Healthy volunteers

Not accepted

Sponsor

Flare Therapeutics Inc.

Last updated on ClinicalTrials.gov

September 24, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites